Nach den Quartalszahlen: Biontech: Geht die Party jetzt weiter? Die neuen Kursziele der Analysten | Diskussion im Forum
eröffnet am 10.05.22 11:17:40 von
neuester Beitrag 24.04.23 12:17:48 von
neuester Beitrag 24.04.23 12:17:48 von
ISIN: US09075V1026 · WKN: A2PSR2 · Symbol: BNTX
99,10
EUR
+1,93 %
+1,88 EUR
Letzter Kurs 18:17:41 · Tradegate
Neuigkeiten
 Smartbroker: Handeln an mehr als 35 Börsen (u.a. Xetra, Nasdaq, Hongkong)  |
04:44 Uhr · kapitalerhoehungen.de |
30.05.23 · Markus Weingran |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,700 | +6.900,00 | |
| 128,00 | +129,47 | |
| 232,12 | +70,89 | |
| 60,35 | +68,81 | |
| 146,71 | +61,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,800 | -22,50 | |
| 18,490 | -23,28 | |
| 2,320 | -24,44 | |
| 26,12 | -33,42 | |
| 33,54 | -44,10 |
Beitrag zu dieser Diskussion schreiben
Feedback
24.4.
China’s Covid Drugmakers Shares Jump Amid Concern Over New Virus Wave
https://uk.news.yahoo.com/china-covid-drugmakers-surge-amid-…
...
Growing concerns that China may be facing a new Covid wave fueled a surge in shares of the nation’s drugmakers Monday as the public fretted over waning immunity.
...
Meanwhile, Zhang Wenhong, one of China’s top Covid advisers, said at a summit last week that vulnerable groups should get a booster shot and citizens should stock up on drugs in preparation for the arrival of new variants.
...
China’s Covid Drugmakers Shares Jump Amid Concern Over New Virus Wave
https://uk.news.yahoo.com/china-covid-drugmakers-surge-amid-…
...
Growing concerns that China may be facing a new Covid wave fueled a surge in shares of the nation’s drugmakers Monday as the public fretted over waning immunity.
...
Meanwhile, Zhang Wenhong, one of China’s top Covid advisers, said at a summit last week that vulnerable groups should get a booster shot and citizens should stock up on drugs in preparation for the arrival of new variants.
...
wenn China den "BioNTech-Piks" in größerem Umfang als bislang bekommen sollte, dann geht's hier vermutlich wieder ab -- mit Angriff auf das Gap vom Januar mMn:
7.11.
...
BioNTech raises the lower end of its 2022 full year financial guidance to include estimated COVID-19 vaccine revenue of €16 - 17 billion
...
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
https://www.ariva.de/news/biontech-announces-third-quarter-2…
..und wieder retour:
...
BioNTech raises the lower end of its 2022 full year financial guidance to include estimated COVID-19 vaccine revenue of €16 - 17 billion
...
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
https://www.ariva.de/news/biontech-announces-third-quarter-2…
..und wieder retour:
28.8.
WSJ: New omicron-specific COVID booster expected to be approved before trial data is in
https://www.marketwatch.com/story/new-omicron-specific-covid…
...
‘The vaccines are safe,’ FDA commissioner says; clearance is similar to approach FDA takes with flu shots
The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.
The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.
Instead, the agency plans to assess the shots using data from other sources such as research in mice, the profiles of the original vaccines and the performance of earlier iterations of boosters targeting older forms of omicron.
“Real world evidence from the current mRNA COVID-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe,” FDA Commissioner Robert Califf said in a recent tweet. The FDA pointed to Califf’s tweets when asked for comment.
...
WSJ: New omicron-specific COVID booster expected to be approved before trial data is in
https://www.marketwatch.com/story/new-omicron-specific-covid…
...
‘The vaccines are safe,’ FDA commissioner says; clearance is similar to approach FDA takes with flu shots
The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.
The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.
Instead, the agency plans to assess the shots using data from other sources such as research in mice, the profiles of the original vaccines and the performance of earlier iterations of boosters targeting older forms of omicron.
“Real world evidence from the current mRNA COVID-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe,” FDA Commissioner Robert Califf said in a recent tweet. The FDA pointed to Califf’s tweets when asked for comment.
...
Antwort auf Beitrag Nr.: 72.117.669 von faultcode am 03.08.22 16:15:00
Trading Spotlight
Diskussion zum Wertpapier
Cybeats kündigt Testauftrag eines S&P 500-Unternehmens für Interactive Home Entertainment an; dringt
Von
Polli Aktien haben genügend Zeit den Bach runter zu gehen 🚶♂️ Warum sollte es hier …
Antwort auf Beitrag Nr.: 71.894.871 von faultcode am 30.06.22 23:32:48das sieht ganz konstruktiv aus derzeit:
!
Dieser Beitrag wurde von SelfMODus moderiert. Grund: Fragen zur Moderation bitte direkt an den Moderator oder an den CommunitySupport.!
Dieser Beitrag wurde von SelfMODus moderiert. Grund: Fragen zur Moderation bitte direkt an den Moderator oder an die CommunityLeitung
Ihr wollt nur nicht die Fakten wahr haben
Durchsuchen
